New Monoclonal Antibodies

  • M. R. Costanzo


The technology for the production of monoclonal antibodies (moabs) was established 20 years ago by Kohler and Milstein[1]. The fusion of myeloma cells with immunized spleen cells produces a hybridoma. Such a cell line possesses both the immortality of myeloma cells and the ability to produce an antibody of a single predetermined specificity. In contrast to polyclonal antibodies, moabs are homogeneous, have greater potency at lower doses, and have a more predictable and consistent effect[1]. Since its introduction, moab technology has become an important diagnostic and therapeutic tool in many areas of medicine. These include the identification of phenotypic markers unique to particular cell types, immunodiagnosis, tumor diagnosis and therapy, functional analysis of cell surface and secreted molecules, and prevention and treatment of organ transplant rejection.


Allograft Rejection Antilymphocyte Globulin Organ Transplant Rejection Immunize Spleen Cell Intrathymic Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Cosimi AB. Antilymphocyte globulin and monoclonal antibodies. In: Morris PJ, editor. Kidney transplantation: principles and practice, 3rd edn. Philadelphia, PA: Saunders; 1988:343.Google Scholar
  3. 3.
    Jaffers GJ, Cosimi AB. Anti-lymphocyte globulin and monoclonal antibodies. In: Morris PJ, editor. Kidney transplantation: principles and practice. 2nd edn. New York. Grune & Stratton; 1984:281.Google Scholar
  4. 4.
    Monaco AP, Biological immunosuppression: polyclonal antilymphocyte sera, monoclonal antibody, and donor-specific antigen. In: Cerilli GJ, editor. Organ transplantation and replacement. Pennsylvania: Lippincott; 1988:83.Google Scholar
  5. 5.
    Cosimi AB, Colvin RB, Burton RC et al. Use of monoclonal antibodies to T cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med. 1981;305:308–14.PubMedGoogle Scholar
  6. 6.
    Gebel HM, Lebeck LK, Jensik SC, Webster K, Bray RA. T cells from patients successfully treated with OKT3 do not react with the T cell receptor antibody. Hum Immunol. 1989;26:123–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Cosimi AB. OKT3: First-dose safety and success. Nephron. 1987;46:12–18.PubMedCrossRefGoogle Scholar
  8. 8.
    Haverty TP, Sander M, Sheahan M: OKT3 treatment of cardiac allograft rejection. J Heart Lung Transplant. 1993;12:591–8.PubMedGoogle Scholar
  9. 9.
    Carrier M, Jenicek M, Pelletier LC. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis. Transplant Proc. 1992;24:2586–91.PubMedGoogle Scholar
  10. 10.
    Ortho Multicenter Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 1985;313:337–42.Google Scholar
  11. 11.
    Abramowicz D, Schandcne L, Goldman M, et al. Release of tumor necrosis factoralpha. interleukin-2 and interferon-gamma in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989;47:606–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Chatenoud L, Reuter A, Legendre C et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med. 1989;320:1420–1.PubMedGoogle Scholar
  13. 13.
    Suthanthiran M, Fotino M, Giggio RR, Chiegh JS, Stenzel KH. OKT3 associated adverse reactions: Mechanistic basis and therapeutic options. Am J Kidney Dis. 1989;l4(Suppl. 2):39–44.Google Scholar
  14. 14.
    First MR, Schroeder TJ, Hariharan S. The OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy). Transplant Proc. 1993;25(Suppl. 1):25–6.PubMedGoogle Scholar
  15. 15.
    Costanzo-Nordin MR. Cardiopulmonary effects of OKT3: determinants of hypotension pulmonary edema, and cardiac dysfunction. Transplant Proc. 1993;25(Suppl. 1):21–24.PubMedGoogle Scholar
  16. 16.
    Goldstein G, Fuccello AJ, Norman DJ, Shield CF III, Colvin RB, Cosimi AB. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation. 1986;42:507–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Jaffers GT, Fuller TC, Cosimi AB, Russel PS, Winn HU, Colvin RB. Monoclonal antibody therapy: anti-idiotypic and non-anti-idiotypic antibodies of OKT3 arising despite intense immunosuppression. Transplantation. 1986;41:572–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Schroeder TJ, First MR, Mansour ME et al. Antimurine antibody formation following OKT3 therapy. Transplantation. 1990;49:48–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Kimball JA, Norman DJ, Shield CF et al. OKT3 antibody response stdy (OARS): a multicenter comparative study. Transplant Proc. 1993;25:558–60.PubMedGoogle Scholar
  20. 20.
    Hammond EH, Wittwer CT, Greenwood J et al. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation. 1990;50:776–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Johnson MR, Mullen GM, O’Sullivan EJ et al. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am J Cardiol. 1994;74:261–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorders following immunosuppression with OKT3 in cardiac transplantation. N Engl J Med. 1991;323:1723–8.Google Scholar
  23. 23.
    Tax WJM, van de Heijden HMW, Willems HW et al. Immunosuppression with monoclonal anti-T3 antibody (WT32) in renal transplantation. Transplant Proc. 1987;19:1905–7.PubMedGoogle Scholar
  24. 24.
    Waid TH, Lucas BA, Amlot P et al. T10B9.1A-31 anti-T-cell monoclonal antibody: Preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis. 1989;l4(Suppl. 2):61–70.Google Scholar
  25. 25.
    Waid TH, Lucas BA, Thompson JS et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation. 1992;51:80–6.CrossRefGoogle Scholar
  26. 26.
    Waid TH, Lucas BA, Thompson JS et al. Treatment of acute cellular kidney allograft rejection T10B9.IA-31 anti-T-cell monoclonal antibody. Transplant Proc. 1989;21:1778–84.PubMedGoogle Scholar
  27. 27.
    Marlin SD, Springer TA. Purified intercellular adhesion moleculc-1 (ICAM-1) is a ligand for lymphocyte function associated antigen (LFA1). Cell. 1987;51:813–19.PubMedCrossRefGoogle Scholar
  28. 28.
    Byrne JG, Smith WJ, Murphy MP, Couper GS, Appleyard RF, Cohn LH. Complete prevention of myocardial stunning, contracture. low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion. J Thorac Cardiovasc Surg. 1992;104:1589–95.PubMedGoogle Scholar
  29. 29.
    Isobc M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allografts after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992;255:1125–7.CrossRefGoogle Scholar
  30. 30.
    Kirkman RL, Shapiro ME, Carpenter CB et al. A randomized prospective trial of anti-TAC monoclonal antibody in human renal transplantation. Transplantation. 1991;51:107–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Soulillou JP, Cantarovich D, Le Mauff B et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med. 1990;322:1175–82.PubMedGoogle Scholar
  32. 32.
    Winter G, Milstein C. Man-made antibodies. Nature. 1991;349:293–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Delmonico FL, Cosimi AB, Kawai T et al. Nonhuman primate responses to murine and humanized OKT4A. Transplantation. 1993;55:722–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Meiser BM, Reiter C, Reichenspurner H et al. Chimeric monoclonal CD4 antibody-a novel immunosuppressant for clinical heart transplantation. Transplantation. 1994;48:419–23.Google Scholar
  35. 35.
    Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes. Immunol Rev. 1992;130:41–68.PubMedCrossRefGoogle Scholar
  36. 36.
    Hamashima T, Stepkowski SM, Smith S, Kahan BD. Induction of transplantation tolerance by a single intrathymic injection of 3M KCl-extracted donor histocompatibility antigens with two doses of anti-rat α/β-T cell receptor monoclonal antibodies. Transplantation. 1994;58:105–7.PubMedGoogle Scholar
  37. 37.
    Keman NA, Knowlcs RW, Bums MJ et al. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin. J Immunol. 1984;133;137–46.Google Scholar
  38. 38.
    Weisdorf D, Filipovich A, McGlave P et al. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazymc-CD5]) plus methotrexate and cyclosporin or prednisone after unrelated donor marrow transplantation. Bone Marrow Transplant. 1993;12:531–6.PubMedGoogle Scholar
  39. 39.
    Schroeder TJ, First MR: Monoclonal antibodies in organ transplantation. Am J Kidney Dis. 1994;23:138–47.PubMedGoogle Scholar
  40. 40.
    Masroor S, Schroeder TJ, Michler RE, Alexander JW, First MR: Monoclonal antibodies in organ transplantation: an overview. Transplant Immunol. 1994;2:176–89.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • M. R. Costanzo

There are no affiliations available

Personalised recommendations